| Identification | Back Directory | [Name]
Dapagliflozin-3-O--D-Glucuronide | [CAS]
1351438-75-9 | [Synonyms]
Dapagliflozin-3-O--D-Glucuronide
Dapagliflozin-3-O-β-D-Glucuronide
Dapagliflozin 3-O-β-D-Glucuronide D5Q: What is
Dapagliflozin 3-O-β-D-Glucuronide D5 Q: What is the CAS Number of
Dapagliflozin 3-O-β-D-Glucuronide D5 | [Molecular Formula]
C27H33ClO12 | [MDL Number]
MFCD34181284 | [MOL File]
1351438-75-9.mol | [Molecular Weight]
584.997 |
| Chemical Properties | Back Directory | [Boiling point ]
857.0±65.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: Soluble; Methanol: Soluble; Water: Soluble | [form ]
A crystalline solid | [pka]
2.81±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport. Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition. | [Uses]
Dapagliflozin 3-O-β-D-Glucuronide is a metabolite of Dapagliflozin (D185380) which is a sodium-glucose transporter 2 inhibitor. | [References]
[1] EDWARD C. CHAO Robert R H. SGLT2 inhibition — a novel strategy for diabetes treatment[J]. Nature Reviews. Drug Discovery, 2010, 9 7: 551-559. DOI: 10.1038/nrd3180
[2] J-S VAN DER WALT. A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment[J]. CPT: Pharmacometrics & Systems Pharmacology, 2013, 2 5: 1-9. DOI: 10.1038/psp.2013.20 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|